ArticleJAC-antimicrobial resistance2025
Eravacycline as a last resort for difficult-to-treat resistant
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Real-World Therapy with Eravacycline for Complex Infections Caused by Carbapenem-Resistant Pathogens with a Focus on Patients with Severe Burns.Infectious diseases and therapy · 2026Article
- Article
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Eravacycline as Salvage Therapy for Severe Intra-Abdominal Infections Caused by Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Case Report: Diagnosis and management of severe pneumonia caused by complex mixed infection with multidrug-resistant bacteria and fungi after liver retransplantation.Frontiers in surgery · 2026Article
- Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To describe eravacycline use as a salvage treatment for ventilator-associated pneumonia (VAP) caused by difficult-to-treat resistant (DTR) Methods: We reported three cases of DTR Results: Eravacycline MICs ranged from 0.25 to 0.75 mg/L. Microbiological success was observed in the three cases, including one patient who was successfully weaned and discharged alive with no further samples submitted for microbiological culture, and two other patients who were repeatedly sampled and remained negative for Conclusions: Eravacycline showed promise as a salvage therapy for DTR
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.